Literature DB >> 21596431

Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex.

Hibah Aldawsari1, Ruangelie Edrada-Ebel, David R Blatchford, Rothwelle J Tate, Laurence Tetley, Christine Dufès.   

Abstract

The possibility of using non-viral gene delivery systems for the treatment of cancer is currently limited by their lower transfection efficacy compared to viral systems. On the basis that amino acids such as arginine, lysine and leucine were involved in enhancing DNA transportation into cells, we hypothesized that the grafting of these amino acids to the highly promising generation 3 diaminobutyric polypropylenimine (DAB) dendrimer would improve its transfection efficacy in cancer cells. In this work we demonstrated that the conjugation of arginine, lysine and leucine to the dendrimer led to an enhanced anti-proliferative activity of the polyplexes, by up to 47-fold for DAB-Lys in T98G cancer cells compared to the unmodified polyplex in vitro. In vivo, the intravenous administration of amino acid-bearing DAB polyplexes resulted in a significantly improved tumor gene expression, with the highest gene expression level observed after treatment with DAB-Lys polyplex. Arginine, lysine and leucine-bearing generation 3 polypropylenimine polymers are therefore highly promising gene delivery systems for gene transfection in tumors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596431     DOI: 10.1016/j.biomaterials.2011.04.079

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  7 in total

1.  Combined Local Pulmonary and Systemic Delivery of AT2R Gene by Modified TAT Peptide Nanoparticles Attenuates Both Murine and Human Lung Carcinoma Xenografts in Mice.

Authors:  Susumu Ishiguro; Nabil A Alhakamy; Deepthi Uppalapati; Jennifer Delzeit; Cory J Berkland; Masaaki Tamura
Journal:  J Pharm Sci       Date:  2016-10-18       Impact factor: 3.534

2.  Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes.

Authors:  Li Ying Lim; Pei Yin Koh; Sukrut Somani; Majed Al Robaian; Reatul Karim; Yi Lyn Yean; Jennifer Mitchell; Rothwelle J Tate; RuAngelie Edrada-Ebel; David R Blatchford; Margaret Mullin; Christine Dufès
Journal:  Nanomedicine       Date:  2015-04-29       Impact factor: 5.307

3.  Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12.

Authors:  Najla Altwaijry; Sukrut Somani; John A Parkinson; Rothwelle J Tate; Patricia Keating; Monika Warzecha; Graeme R Mackenzie; Hing Y Leung; Christine Dufès
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 4.  Shedding light on gene therapy: Carbon dots for the minimally invasive image-guided delivery of plasmids and noncoding RNAs - A review.

Authors:  Reza Mohammadinejad; Arezoo Dadashzadeh; Saeid Moghassemi; Milad Ashrafizadeh; Ali Dehshahri; Abbas Pardakhty; Hosseinali Sassan; Seyed-Mojtaba Sohrevardi; Ali Mandegary
Journal:  J Adv Res       Date:  2019-01-18       Impact factor: 10.479

5.  Lactoferrin- and Dendrimer-Bearing Gold Nanocages for Stimulus-Free DNA Delivery to Prostate Cancer Cells.

Authors:  Jamal Almowalad; Partha Laskar; Sukrut Somani; Jitkasem Meewan; Rothwelle J Tate; Christine Dufès
Journal:  Int J Nanomedicine       Date:  2022-03-25

6.  Self-assembling HA/PEI/dsRNA-p21 ternary complexes for CD44 mediated small active RNA delivery to colorectal cancer.

Authors:  Chen-Lin Feng; Yan-Xing Han; Hui-Hui Guo; Xiao-Lei Ma; Zhi-Qiang Wang; Lu-Lu Wang; Wen-Sheng Zheng; Jian-Dong Jiang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Tyrosine-Modification of Polypropylenimine (PPI) and Polyethylenimine (PEI) Strongly Improves Efficacy of siRNA-Mediated Gene Knockdown.

Authors:  Sandra Noske; Michael Karimov; Achim Aigner; Alexander Ewe
Journal:  Nanomaterials (Basel)       Date:  2020-09-10       Impact factor: 5.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.